VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE

Robert Schultz  1     Ibrahim Diakite  2     John Carter  2     Sonya Snedecor  2     Robin Turpin  2    
1 Takeda Pharmaceuticals, Deerfield, United States
2 Pharmerit International, Bethesda, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing